Zydus Lifesciences Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Enzalutamide Tablets, available in 40 mg and 80 mg strengths. This significant approval marks a pivotal moment for the company, expanding its portfolio of cancer treatments and positioning it for a more substantial presence in the global […]
Zydus Lifesciences Limited has achieved a significant milestone in the pharmaceutical industry. The company recently received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg. This approval marks a major victory for Zydus as the capsules, an androgen receptor inhibitor, are critical for treating metastatic castration-resistant prostate […]
Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has enhanced its strategic position in the oncology market by securing an exclusive global license for opevesostat (MK-5684/ODM-208) and other CYP11A1 targeting candidates, following a mutual agreement with Orion Corporation. This pivotal deal marks a significant advancement in the treatment of prostate […]
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study of TLX592, marking a significant advancement in targeted alpha therapy (TAT) for prostate cancer. This milestone is especially noteworthy as TLX592 incorporates Telix’s proprietary RADmAb engineered antibody technology, promising a new era in cancer treatment efficacy and […]
In a strategic move to revolutionize cancer treatment, AstraZeneca has announced its definitive agreement to acquire Fusion Pharmaceuticals Inc., a pioneer in the development of next-generation radioconjugates (RCs) for cancer therapy. This acquisition is a pivotal step for AstraZeneca in fulfilling its vision to transform cancer care, aiming to substitute conventional treatments such as chemotherapy […]
Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a trailblazer in the oncology sector specializing in the development of next-generation radiopharmaceuticals, has announced a landmark exclusive worldwide license agreement with Heidelberg University and Euratom, represented by the European Commission, Joint Research Centre. This pivotal agreement confers upon Fusion the exclusive worldwide rights to develop, manufacture, and commercialize compounds […]
Clarity Pharmaceuticals (ASX: CU6), a clinical stage radiopharmaceutical company, announced significant progress in the SECuRE trial, marking a pivotal step in cancer treatment research. The company, dedicated to developing next-generation products for better cancer treatment outcomes, has successfully completed the first stage of cohort 3 in this Phase I/IIa trial. Promising Results in Advanced Prostate […]
Curium, a leading figure in the global nuclear medicine sector, has proudly announced the successful completion of patient enrollment in the pivotal Phase 3 ECLIPSE trial. This significant accomplishment represents a major leap forward in the quest to treat metastatic castration-resistant prostate cancer. ECLIPSE Trial: A Study in Progress The ECLIPSE trial, a Phase 3, […]
Novartis has received the approval of the European Commission (EC) for Pluvicto (lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy for advanced prostate cancer. Following the approval, Pluvicto has become the first targeted radioligand therapy to be commercially available to prevent advanced prostate cancer in individuals. Pluvicto in combination with androgen deprivation therapy (ADT) with […]
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is engaged in developing small molecule therapeutics for aggressive cancers and rare tumors. On the other hand, Advaxis is focused on developing immunotherapies based on a technology that makes use of […]